Data Suggest Doctors Wait 12 Months Before Buprenorphine Tapers

Stopping buprenorphine is one of the most consequential decisions in medication-assisted treatment (MAT) for opioid use disorder, and a new clinical review lays out what the evidence supports. Tapering buprenorphine should be a slow, voluntary process, started only after a substantial period of stability, because the alternative carries a measurable overdose risk.

The review appears in the August 2026 issue of American Family Physician and was written by Maria Gabriela Castro, MD, H. Claire West, MD, and E. Blake Fagan, MD, of the University of North Carolina at Chapel Hill School of Medicine. It synthesizes existing evidence and grades each recommendation by the strength of the research behind it.

The Importance of Medical Detox

Opioid use disorder affects roughly 9.5 million people in the United States, and opioid-related overdoses contributed to more than 50,000 deaths in 2024. Those deaths were driven primarily by illicitly manufactured fentanyl rather than heroin or prescription opioids.

Against that backdrop, buprenorphine is not a temporary bridge through withdrawal. It reduces opioid overdose risk and all-cause mortality by more than 50% each. Coming off it is therefore a clinical decision with real stakes, not a milestone to be rushed toward.

The authors note that discontinuation is common and usually initiated by the patient rather than the clinician.

Understanding Buprenorphine

Buprenorphine is a partial agonist at the mu-opioid receptor. It treats cravings and relieves withdrawal symptoms, and it has a ceiling effect for euphoria and respiratory depression, though not for pain relief. That ceiling is a large part of why it is considered safer than full agonist opioids.

Any clinician with Schedule III prescribing authority can prescribe it in any setting, including primary care, and it can be dispensed for take-home dosing from any commercial pharmacy.

What the Evidence Supports

The review sets out four graded recommendations:

• Buprenorphine maintenance should continue as long as it benefits the patient, to support long-term remission and reduce overdose risk. This carries the strongest evidence rating, based on systematic reviews, meta-analyses, and national practice guidelines from the American Society of Addiction Medicine.
• Patients should complete at least 12 months of maintenance before tapering buprenorphine to decrease overdose risk.
• Tapers should be slow and individualized. Dose reductions of no more than 2 mg per month should be considered, with adjustments made no more than every one to two months.
• Clinicians should provide close follow-up after tapering buprenorphine, both to support recovery and to assess whether treatment needs to restart.

Longer maintenance and slower taper rates are associated with lower overdose risk, lower rates of opioid use, and higher rates of taper completion.

Dose Reduction Is a Legitimate Endpoint

One of the more practical points in the review is that complete cessation does not have to be the goal. For some patients, a sustained lower dose is a more feasible endpoint than stopping entirely.

The optimal duration of maintenance therapy is not known, so the authors argue the decision to discontinue should be clinically supported, patient-centered, and voluntary. Shared decision-making, flexible tapering plans, and overdose prevention are framed as the three things that reduce risk.

The review also supports adjunctive medications to manage withdrawal symptoms during a taper, alongside harm reduction measures including naloxone provision and ongoing follow-up.

Medical Safety Callout

Do not stop or reduce buprenorphine on your own. Tolerance falls quickly once the medication is reduced or stopped, and returning to previous opioid use at that point carries a serious overdose risk. Any change to a buprenorphine dose should be planned with the prescribing clinician, and naloxone should be available throughout a taper and after it ends.

Separately, never attempt alcohol or benzodiazepine detox without medical supervision. Withdrawal from either can produce seizures and, in the case of alcohol, delirium tremens, both of which can be life-threatening.

Levels of Detox Care

Where this care happens depends on the clinical picture. ASAM Level 4 is medically managed intensive inpatient care, appropriate when withdrawal carries significant medical risk. Level 3.7 is medically monitored inpatient care with 24-hour nursing. Level 3.2 is clinically managed residential care for people whose withdrawal is expected to be less medically complex.

Buprenorphine tapering as described in this review is typically managed in an outpatient setting over many months, which is precisely why the pacing recommendations matter.

Finding Medical Detox and MAT

If you are on buprenorphine and considering stopping, or looking for a program that offers medication-assisted treatment:

• Ask whether the program supports long-term maintenance rather than pushing toward a fixed end date.
• Confirm the taper schedule in writing before starting, including the size and frequency of reductions.
• Ask what follow-up looks like after a taper is complete.
• Make sure naloxone is provided and that you know how to use it.

Detox.com’s directory lists medically supervised detox and MAT providers by location, level of care, and insurance accepted. SAMHSA’s National Helpline is available at 1-800-662-4357 for treatment referrals.